During the corresponding time, Exagen Inc recorded a revenue increase by 21.63 % year on year, sequentially revenue grew by 15.9 %. While revenue at the Exagen Inc 's corporate clients
Exagen Inc's Comment on Sales, Marketing and Customers
The company provides diagnostic testing services to rheumatologists, primary care physicians, other specialists, and their patients. Its primary testing product, AVISE® CTD, is utilized in clinical settings to assist in decision-making for autoimmune diseases, particularly connective tissue diseases (CTDs) and related conditions with overlapping symptoms. AVISE® CTD supports clinicians in the diagnosis of CTDs such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company serves doctors, hospitals, healthcare systems, and payors.
Exagen Inc’s Comment on Sales, Marketing and Customers
The company provides diagnostic testing services to rheumatologists, primary care physicians, other specialists, and their patients. Its primary testing product, AVISE® CTD, is utilized in clinical settings to assist in decision-making for autoimmune diseases, particularly connective tissue diseases (CTDs) and related conditions with overlapping symptoms. AVISE® CTD supports clinicians in the diagnosis of CTDs such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company serves doctors, hospitals, healthcare systems, and payors.
Sources:
Exagen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Exagen Inc’s corporate clients.
For your research, we’ve provided 9 tables on Exagen Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
186.79 %